• Kevin L Anderson, Mohamed A Adam, Samantha Thomas, Sanziana A Roman, and Julie A Sosa.
• Duke University School of Medicine, Durham, NC 27710, USA. Electronic address: kla24@duke.edu.
• Am. J. Surg. 2017 Apr 1; 213 (4): 601-605.

BackgroundPublished data examining the impact of minimally invasive distal pancreatectomy (MIDP) on survival are generally limited to experiences from high-volume institutions. Our aim was to compare utilization of adjuvant chemoradiation and time from surgery until its initiation following MIDP vs. open surgery (ODP) at a national level.MethodsAdult patients undergoing distal pancreatectomy for Stage I and II pancreatic adenocarcinoma were identified from the National Cancer Data Base, 2010-2012.ResultsA total of 1807 patients underwent distal pancreatectomy for adenocarcinoma at 506 institutions (27.9% MIDP). After adjustment, those who underwent MIDP were more likely to have complete tumor resections and a shorter hospital length of stay. Patients undergoing MIDP vs. ODP were more likely to receive adjuvant chemotherapy; time to initiation of adjuvant chemotherapy or radiation was not different between groups. After adjustment, overall survival for MIDP vs. ODP remained similar (HR 0.85, CI 0.67-1.10, p = 0.21).ConclusionMIDP is associated with increased use of adjuvant chemotherapy; further study is needed to understand the etiology and impact of this association.Copyright © 2017 Elsevier Inc. All rights reserved.

33 keywords...

hide…